|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial. |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Dodatne storitve |
|
|
© 2024 SFX by Ex Libris Inc. | Politika piškotkov
CrossRef Omogočeno
|